aom0498, as the first selective specific muscle relaxant antagonist in china, inactivates both rocuronium and vecuronium and has rapid onset and high safety. it is inactive in vivo that no metabolic reaction of aom0498 was observed.
with independent intellectual property rights in 12th five-year 13th five-year, as a national major new drug project huge market potentialanti-thrombotic aom0315
aom0315 is a novel antithrombotic drug that eliminates the risk of internal haemorrhage of other antithrombotics and has a vascular repair effect. it can be used for the prevention and treatment of thrombus. it may become a milestone in the field of antithrombotics.
intravenous anesthetic aom0765
aom0765 has rapid onset with good water solubility. patients receiving it recover quickly from anesthesia. there is no accumulation after continuous infusion. it may be the first choice of anesthesia induction and maintenance in the future.
weight-loss drug aom1110
aom1110 accelerates the elimination of fat and cannot be absorbed in vivo. it has good efficacy of losing and controlling weight and reduces incidence of diabetes and vascular diseases. it does not affect neuromuscular system. not being excreted by liver, aom1110 has high safety.
hangzhou adamerck pharmlabs inc telephone / fax：86-571-8534 1830 e-mail：international co-operation：global@adamerck.com
domestic cooperation：info@adamerck.com address：building 7, no. 39 xiangyuan road, gongshu district, hangzhou, zhejiang
凯发娱乐赞助 copyright 2016 ：hangzhou adamerck pharmlabs inc
